<DOC>
	<DOCNO>NCT03043326</DOCNO>
	<brief_summary>The purpose study evaluate acceptability , use adherence pre-exposure prophylaxis ( PrEP ) program use co-formulation tenofovir disoproxil fumarate 300 mg/emtricitabine 200 mg ( TDF/FTC ) administer daily mouth , four health facility one community-based organization provide health care service MSM transgender woman . This Observational , longitudinal , multicenter , open-label study evaluate acceptability , use adherence TDF/FTC-based PrEP volunteer men sex men transgender woman substantial high risk acquire HIV , prescribe PrEP , follow clinical guideline prevent HIV infection U.S. Centers Disease Control Prevention ( 2014 ) World Health Organization ( 2015 ) . Follow-up : Participants follow 96 week ( approximately two year ) start prophylactic treatment . Implementation Target Population : Adults ( ≥18 year age ) , without HIV infection diagnosis , prescribe PrEP substantial risk acquire HIV infection accord international guideline HIV prevention . Sample Size : 1,000 participant Implementation Sites : 1 . Asociación Civil Impacta Salud Educación , Barranco study site 2 . Asociación Civil Impacta Salud Educación , San Miguel study site 3 . Asociación Civil Selva Amazónica , ACSA study site 4 . Asociación Vía Libre , Vía Libre study site 5 . Espacio Común , Epicentro study site Primary Objectives : 1 . Describing acceptability socio-demographic sexual behavior correlate use PrEP . 2 . Evaluate persistence use PrEP correlate risk behavior 3 . Evaluating adherence PrEP use self-reporting pill count Secondary Objectives : 1 . Describing change time risky sexual behavior among study participant . 2 . Describing number participant acquire HIV infection . 3 . Evaluate deviation indication use PrEP self- reporting sale share third party .</brief_summary>
	<brief_title>Demonstration Project Feasibility Implement PrEP MSM TG Women</brief_title>
	<detailed_description>HYPOTHESIS 1 . Hypothesis 1 . The use PrEP base daily intake TDF/FTC acceptable MSM transgender woman acceptance correlate knowledge PrEP sexual risk behavior . 2 . Hypothesis 2 . Adherence duration use PrEP base daily intake TDF/FTC correlate level education , socioeconomic level , knowledge PrEP risk behavior . OBJECTIVES AND DESIGN OF THE STUDY Primary Objectives : 1 . Describing acceptability socio-demographic sexual behavior correlate use PrEP . 2 . Evaluate persistence use PrEP correlate risk behavior 3 . Evaluating adherence PrEP use self-reporting pill count Secondary Objectives : 1 . Describing change time risky sexual behavior among study participant . 2 . Describing number participant acquire HIV infection . 3 . Evaluating deviation indication use PrEP self-reporting sale share third party . Study Design This observational , longitudinal , multicenter , open-label study evaluate acceptability , use adherence PrEP MSM transgender woman population . Four nongovernmental organization health center one community-based organization city Lima Iquitos participate observational study . The study enroll 1,000 participant ( estimate 200 participant per study site ) period 72 week ( one half year ) . Each participant follow 96 week ( two year ) start PrEP . The estimate duration study implementation 192 week ( four year ) . After enrollment , participant must attend assessment visit 4 week , 12 week every 12 week complete participation study . IMPLEMENTATION TARGET POPULATION Description Study Population This PrEP research project implement volunteer MSM transgender woman without diagnosis HIV infection risk acquire HIV sexual behavior prior observational study enrollment , prescribe PrEP primary care provider accord clinic guideline U.S. CDC ( 2014 ) WHO ( 2015 ) RESEARCH SITES Each one propose site ability meet specific project implementation procedure protocol . Their investigator show comply national regulation , include good clinical practice protection human research subject . The propose site experience provide comprehensive health care service target population additionally participate research study evaluate different strategy HIV prevention . Based profile , sit ideal implement PrEP Demonstration Project MSM transgender woman . The site propose project : 1 . Asociación Civil Impacta Salud Educación , Barranco site 2 . Asociación Civil Impacta Salud Educación , San Miguel site 3 . Asociación Civil Selva Amazónica , ACSA site 4 . Asociación Vía Libre , Vía Libre site 5 . Espacio Común ( Epicentro ) , Epicentro site The participation health facility Ministry Health promote give information obtain study cost-effectiveness program model determine feasibility escalation various health center may support public fund long term . RECRUITMENT AND RETENTION Recruitment The recruitment volunteer study carry implementation mass medium campaign promote perform HIV infection diagnostic testing . Virtual broadcast channel social networking platform use . In message place form banner link redirect user websites participate institution , HIV test diagnosis promote time study implement . Retention Participants The retention study participant govern follow principle : 1 . Warm care site establish friendly relationship participant staff charge care ; 2 . Quality care , include establish procedure , permanent timely information user , well short wait time . Since primary objective project determine feasibility implement PrEP program MSM transgender woman risk acquire HIV , study promote active retention participant . PRE-EXPOSURE PROPHYLAXIS TREATMENT Formulation/Content TDF/FTC co-formulation contains fix TDF dose 300 mg ( equal 245 mg tenofovir disoproxil 136 mg tenofovir ) 200 mg FTC . Regimen Administration Study participant follow prescription issue primary health care provider . The PrEP medication provide cost Gilead Sciences , Inc . Product Dispensing After receive prescription sign primary care provider participant , pharmacist site responsible dispense medication participant visit . At start PrEP visit , pharmacist dispense one bottle first follow-up visit ( week 4 ) dispense two bottle . At subsequent visit take place every 12 week , three bottle dispense . All study participant advise medication share . Study participant report loss theft medication provide additional medication . Particularly Espacio Común site , lack register pharmacy allows storage dispense product , medication dispense Barranco de Asociación Civil Impacta Salud Educación site pharmacy . In scenario , prescription issue Espacio Común , participant go pharmacy describe medication dispense . It important mention four block Espacio Común site Barranco site Asociación Civil Impacta Salud Educación . Given geographical proximity , consider problem access study medication . Product Accounting . The pharmacist Barranco San Miguel sit Asociación Civil Impacta Salud Educación , Asociación Civil Selva Amazónica Asociación Vía Libre responsible maintain complete update record accounting product receive acquire . All unused product return central pharmacy study locate Barranco site Asociación Civil Impacta Salud Educación project end . Adherence Study Medication . Adherence PrEP make count returned tablet schedule visit self-reporting medication intake use questionnaire apply interviewer .</detailed_description>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Be prescribe PrEP Male biological sex ; Age ≥18 year ; Willing able provide write informed consent ; Signs symptom acute retroviral syndrome ; Upon enrollment , condition , base opinion investigator designee , prevents participant provide informed consent ; make participation project unsafe ; complicates interpretation result ; somehow interfere achievement project objective</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pre-exposure Prophylaxis</keyword>
	<keyword>MSM transgender woman</keyword>
</DOC>